Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells

Preferred Label : Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells;

NCIt synonyms : Autologous Anti-CD19/CD20 Bispecific Nanobody-derived CAR-T Cells; Autologous Anti-CD19/20 Bispecific CAR-T Cells; Autologous CD19/CD20 Bispecific CAR-T Cells;

NCIt definition : A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that is nanobody-based and specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19/CD20 bispecific nanobody-based CAR-T cells target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.;

NCI Metathesaurus CUI : CL1406191;

Details

Origin ID

C172057;

UMLS CUI

C5419436;

Semantic type(s)
- Cell [UMLS semantic type]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients